medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2022, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (3)

Promyelocytic leukemia: oncogenetic and molecular approaches in the precision´s medicine era

Barroso SG, Hernández PC, Garrote SH

Language: Spanish
References: 17
Page: 1-10
PDF size: 529.03 Kb.


ABSTRACT

Introduction: The study of the molecular pathogenesis of promyelocytic leukemia revolutionized the foundations of personalized medicine by identifying the PML/RARαoncoprotein as a target for therapies directed at the founding oncogenetic mechanism of the disease. However, in recent decades, other discoveries that provide more information about their biogenesis and development, and their potential impact on the implementation of diagnostic techniques and prognostic tools as an expression of the rapid improvement of translational medicine.
Objective: To expose the main discoveries in the current oncogenetic and molecular mechanisms in promyelocytic leukemia.
Methods: An exhaustive search was carried out in databases such as Scielo, Pubmed, ScienceDirect, Redalyc, Google Scholar, and updated articles published in the last 5 years in English and Spanish were used as references. An analysis and summary of the bibliography was carried out and the most important aspects related to the subject were taken.
Analysis and synthesis of information: the main contributions of molecular biology to the knowledge of the origin of this entity were addressed, beyond the classical approach based on the PML/RARα gene, as well as its variants and other aspects of interest in the monitoring of the illness.
Conclusions: The genetic characteristics of this disease show a mutational landscape different from that of other malignant myeloid neoplasms and point out with special emphasis the importance of clinical-biological integration to facilitate, improve and develop the comprehensive care process for patients with malignant blood diseases.


REFERENCES

  1. Ryan MM. Acute Promyelocytic Leukemia: A Summary. J Adv Pract Oncol. 2018;9(2):178-87. PMID: 30588352

  2. Noguera NI, Catalano G, Banella C, Divona M, Faraoni I, Ottone T, et al2. . Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies. Cancers (Basel). 2019;11(10):1591. DOI: https:// 10.3390/cancers11101591

  3. Liquori A, Ibañez M, Sargas C, Sanz MÁ, Barragán E, Cervera J. Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene. Cancers (Basel). 2020;12(3):624. DOI: https:// 10.3390/cancers12030624

  4. Barroso Sánchez G, Hernández Padrón C. Terapia dirigida a dianas moleculares: perspectiva actual en la leucemia promielocítica. Rev cubana Hematol Inmunol Hemoter. 2021[acceso 19/07/2021];37(3).Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/1481 4.

  5. Jimenez JJ, Chale RS, Abad AC, Schally AV. Acute promyelocytic leukemia (APL): a review of the literature. Oncotarget. 2020;11(11):992-1003. DOI: https:// 10.18632/oncotarget.27513

  6. Wang Y, Wu N, Liu D, Jin Y. Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment. Curr Genomics. 2017;18(5):378-84. DOI: https:// 10.2174/138920291866617032911034979

  7. Hsu KS, Kao HY. PML: Regulation and multifaceted function beyond tumor suppression. Cell Biosci. 2018;8:5. DOI: https:// 10.1186/s13578-018-0204

  8. De Thé H, Pandolfi PP, Chen Z. Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure. Cancer cell. 2017;32(5):552-60. DOI: https://doi.org/10.1016/j.ccell.2017.10.0028.

  9. Cingam SR, Koshy NV. Acute Promyelocytic Leukemia (APL, APML). In: StatPearls Treasure Island (FL): StatPearls Publishing; 2022 Jan-. PMID: 29083825.

  10. Geoffroy MC, de Thé H. Classic and VariantsAPLs, as Viewed from a Therapy Response. Cancers (Basel). 2020;12(4):967. DOI: https:// 10.3390/cancers12040967

  11. Mannan A, Muhsen IN, Barragán E, Sanz MA, Mohty M, Hashmi SK, et al . Genotypic and Phenotypic Characteristics of Acute Promyelocytic Leukemia Translocation Variants. Hematol Oncol Stem Cell Ther. 2020 Dec;13(4):189-201. doi: 10.1016/j.hemonc.2020.05.007.

  12. Sobas M, Talarn-Forcadell MC, Martínez-Cuadrón D. PLZF-RARα, NPM1-RARα, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review. Cancers (Basel). 2020;12(5):1313. DOI: https:// 10.3390/cancers12051313

  13. Moosavi MA, Djavaheri-Mergny M. Autophagy: New Insights into Mechanisms of Action and Resistance of Treatment in Acute Promyelocytic leukemia. Int J Mol Sci. 2019;20(14):3559. DOI: https:// 10.3390/ijms20143559110

  14. Boulanger M, Paolillo R, Piechaczyk M, Bossis G. The SUMO Pathway in Hematomalignancies and Their Response to Therapies. Int J Mol Sci. 2019;20(16):3895. DOI: https:// 10.3390/ijms20163895111

  15. Picharski GL, Andrade DP, Fabro ALMR. The Impact of Flt3 Gene Mutations in Acute Promyelocytic Leukemia: A Meta-Analysis. Cancers (Basel). 2019;11(9):1311. DOI: https:// 10.3390/cancers11091311113

  16. Coccaro N, Tota G, Anelli L, Zagaria A, Specchia G, Albano F. Digital PCR: A ReliableTool for Analyzing and MonitoringHematologicMalignancies. Int J Mol Sci. 2020;21(9):3141. DOI: https:// 10.3390/ijms21093141.115

  17. Cilloni D, Petiti J, Rosso V, Andreani G, Dragani M, Fava C, et al17. . Digital PCR in Myeloid Malignancies: ¿Readyto ReplaceQuantitative PCR? Int J Mol Sci. 2019;20(9):2249. DOI: https:// 10.3390/ijms20092249




2020     |     www.medigraphic.com